FibroGen China

Commitment to Commercial Expansion in the Chinese Market

We are committed to expanding access to transformative medical treatment for patients in China. Roxadustat has gained notable traction in China's healthcare landscape. Roxadustat is currently the category leader in brand share in China for the treatment of anemia in chronic kidney disease (CKD). Healthcare providers in China have increasingly prescribed roxadustat due to its demonstrated efficacy, tolerability, and safety profile. Roxadustat’s approval by the Chinese Health Authority has played a pivotal role in its widespread adoption, offering a valuable alternative for managing anemia in patients with CKD who are on dialysis and patients who are not on dialysis. The convenience of oral administration and the reduced need for traditional injectable erythropoiesis-stimulating agents have contributed to its acceptance among both physicians and patients, marking a significant advancement in the treatment landscape for those suffering from anemia of chronic kidney disease in China.

​

Chemotherapy-induced anemia remains a significantly under-addressed concern in China. Despite the prevalence of anemia as a common side effect of chemotherapy, there is a notable gap in the attention and treatment provided to affected individuals. This under-treatment of chemotherapy-induced anemia not only compromises the quality of life for cancer patients but also hinders the effectiveness of cancer treatments. FibroGen and our partner AstraZeneca filed a supplemental new drug application with the China Health Authority for roxadustat in patients with chemotherapy-induced anemia and expect an approval decision in mid-2024. The potential addition of the chemotherapy-induced anemia indication would create an additional catalyst to the continued sales growth of roxadustat in China.